JOURNAL OF MENTAL HEALTH AND BEHAVIORAL SCIENCES
Apr-Jun 2024, VOL. 2, ISSUE 2, pp. 25-29
https://doi.org/10.61577/jmhbs.2024.1000010

RESEAPRO JOURNALS

REVIEW

OPEN ACCESS

Cognitive behavioral therapy vs. pharmacotherapy: a comparative study on managing generalised anxiety disorder

Suprita Panda

Department of Zoology, North Odisha University, Odisha, India

ABSTRACT

Generalized Anxiety Disorder (GAD) is a prevalent mental health condition characterized by persistent, excessive worry that significantly disrupts daily functioning. Effective management of GAD involves two primary therapeutic strategies: Cognitive Behavioral Therapy (CBT) and pharmacological intervention. CBT is a structured psychotherapeutic approach designed to modify dysfunctional thought patterns and behaviors contributing to anxiety, while pharmacotherapy primarily employs selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines to alleviate symptoms. This analysis presents a comparative evaluation of both treatment modalities, focusing on their efficacy, long-term outcomes, adverse effects, and patient adherence. Evidence indicates that CBT provides sustainable therapeutic benefits by fostering skill acquisition, whereas pharmacotherapy offers rapid symptomatic relief, particularly beneficial in acute settings. The combined use of CBT and medication demonstrates synergistic effects, enhancing clinical outcomes and preventing relapse. This review aims to guide healthcare providers and patients in making informed treatment decisions based on individual symptom severity, therapeutic response, and patient preference. Further research is warranted to explore the long-term effectiveness of integrated treatment strategies across diverse patient populations to optimize care outcomes.

KEYWORDS

Pharmacotherapy; Anxiety treatment comparison; Psychotherapy; Cognitive Behavioral Therapy (CBT); Treatment efficacy

ARTICLE HISTORY

Received 05 April 2024;
Revised 30 April 2024;
Accepted 06 May 2024

Introduction

Generalized Anxiety Disorder (GAD) is a chronic mental health condition marked by excessive worry across various aspects of life. The lifetime prevalence of GAD is estimated to be between 4-7%, with symptoms often starting in adolescence or early adulthood. Historically, mental health professionals misdiagnosed anxiety due to its overlapping physical symptoms, such as gastrointestinal discomfort and insomnia, but awareness and diagnostic methods have improved over time. GAD presents cognitive, emotional, and physiological symptoms, including irritability, fatigue, muscle tension, and restlessness. It interferes significantly with social and occupational functioning. Women are more frequently affected than men due to a combination of biological and social factors. The disorder is often comorbid with depression and substance use disorders, further complicating the diagnosis and management [1].

Management of GAD revolves around two primary treatment modalities: Cognitive Behavioral Therapy (CBT) and pharmacotherapy. CBT works by restructuring negative thought patterns to modify behavioral responses, while pharmacotherapy, primarily using selective serotonin reuptake inhibitors (SSRIs) or benzodiazepines, targets neurochemical imbalances. CBT offers lasting results by teaching coping strategies that patients can apply independently, whereas pharmacotherapy provides rapid relief, especially for acute symptoms. Both treatments, however, have limitations—CBT demands patient commitment over several sessions, and pharmacotherapy carries risks of side effects, including dependency with prolonged use of benzodiazepines [2].

While CBT and pharmacotherapy are effective individually, each has drawbacks. Access to CBT may be limited by geographic and financial barriers, while pharmacotherapy can result in side effects such as sexual dysfunction, nausea, or withdrawal symptoms. Additionally, not all patients respond equally to a single form of treatment, and the long-term use of benzodiazepines poses risks of dependency and withdrawal symptoms, which limits their applicability for sustained treatment. Despite the individual success of CBT and pharmacotherapy, research indicates the need for a more integrated treatment approach. Current studies suggest that combining these modalities may enhance therapeutic outcomes by addressing both the cognitive and neurochemical aspects of GAD. However, comprehensive trials investigating the efficacy of combined treatments across diverse patient populations remain limited [3].

There is also a need for personalized treatment models to address specific patient needs, such as those with severe or treatment-resistant GAD. This study aims to evaluate the comparative and combined effectiveness of CBT and pharmacotherapy for the management of GAD. The objective is to provide clinicians with evidence-based insights to tailor treatment strategies according to symptom severity, patient preferences, and risk factors. Optimizing the use of combined therapies could improve patient adherence, minimize relapse rates, and enhance overall outcomes in GAD management. Further research into long-term effects and real-world applications of these strategies is necessary to close existing gaps and offer better care for individuals with GAD [4].

***Correspondence:** Ms. Suprita Panda, Department of Zoology, North Odisha University, Odisha, India, e-mail: supritapanda106@gmail.com

Cognitive Behavioral Therapy (CBT) for GAD

Core components of CBT

CBT is one of the most well-established and widely used therapeutic approaches for treating anxiety disorders, including GAD. It is a structured, time-limited intervention that focuses on identifying and modifying maladaptive thought patterns and behaviors that contribute to anxiety. One of the key techniques in CBT is cognitive restructuring. This process teaches patients how to challenge and reframe their irrational thoughts or catastrophic thinking. For example, an individual with GAD may frequently expect the worst possible outcome in different situations [5,6]. CBT helps them replace these negative thoughts with more balanced and realistic assessments. Another key component is exposure therapy, where individuals are gradually exposed to feared situations in a controlled manner, reducing avoidance behaviors. Behavioral activation, another important element, involves encouraging patients to engage in meaningful activities, which can help decrease worry and promote a sense of accomplishment. CBT is typically delivered over 12 to 20 sessions, but the skills learned can be applied for life [7].

Mechanisms of action

The mechanisms by which CBT functions are founded on the idea that dysfunctional thoughts and behaviors contribute to and worsen anxiety. CBT instructs individuals to understand the cyclical pattern of anxiety: detrimental thoughts result in emotional turmoil, leading to avoidance or safety-seeking actions, which in turn reinforces the anxiety [8]. By disrupting this cycle, individuals can lessen their anxiety. Techniques like relaxation training and mindfulness are frequently incorporated into CBT frameworks to assist people in managing their physical anxiety symptoms, such as muscle tightness and rapid heartbeat (Figure 1). Moreover, CBT equips individuals with strategies to enhance resilience by teaching them how to tackle problems and confront challenges more successfully. Over time, these skills not only alleviate existing symptoms but also aid in preventing future anxiety incidents, making CBT an essential resource for sustained recovery [9].



Figure 1. Comparative analysis of the mechanisms of SSRI and Benzodiazepines in CBT.

Efficacy in treating GAD

CBT has repeatedly demonstrated its effectiveness in treating GAD across numerous randomized controlled trials and meta-analyses. Research suggests that 60-80% of individuals participating in CBT for GAD see meaningful symptom improvements [10]. CBT is as effective as medication, but it offers the added benefit of longer-lasting effects. While medications provide relief only during their use, the skills gained through CBT empower patients to manage their anxiety over the long term. Research indicates that CBT also has a lower risk of relapse compared to medication once treatment has concluded. Furthermore, CBT is highly adaptable, allowing therapists to tailor their approach to meet the unique needs of each individual, whether that focuses on cognitive restructuring, behavioral techniques, or a combination of both [11].

Pharmacotherapy for GAD

Commonly prescribed medications (SSRIs, Benzodiazepines)

Pharmacotherapy plays a central role in the management of GAD, particularly for individuals with moderate to severe symptoms. The most commonly prescribed medications for GAD are Selective Serotonin Reuptake Inhibitors (SSRIs), such as sertraline, fluoxetine, and escitalopram. SSRIs are favored due to their efficacy and relatively favorable side effect profile compared to older classes of medications, such as tricyclic antidepressants [12]. Another commonly used class of drugs for GAD is benzodiazepines, which include medications like lorazepam and diazepam. Benzodiazepines are primarily used for short-term relief of acute anxiety symptoms due to their sedative effects. However, their use is limited due to the risk of dependency and tolerance. For individuals who do not respond to SSRIs, serotonin-norepinephrine reuptake inhibitors (SNRIs) or atypical antipsychotics may be considered as alternative options [13].

Mechanisms of action

SSRIs function by increasing the availability of serotonin, a neurotransmitter associated with mood regulation, in the brain [14]. By blocking the reuptake of serotonin, these medications help stabilize mood and reduce anxiety symptoms. Benzodiazepines, on the other hand, act by enhancing the activity of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter that promotes relaxation and reduces neural excitability. While benzodiazepines are effective for the immediate relief of anxiety, they do not address the underlying cognitive and emotional processes that maintain GAD, which is why they are typically recommended only for short-term use. SSRIs, in contrast, can take several weeks to begin working but offer more sustainable anxiety reduction over time, especially when used in conjunction with psychotherapy (Figure 2) [15].



Figure 2. Flowchart explaining the mechanism of action in Pharmacotherapy for GAD treatment.

https://doi.org/10.61577/jmhbs.2024.1000010

Side effects and risks

Pharmacotherapy, while effective, is not without its risks and side effects. SSRIs, although generally well-tolerated, can cause a range of side effects, including nausea, insomnia, sexual dysfunction, and, in some cases, increased anxiety during the initial weeks of treatment [16]. Additionally, discontinuation of SSRIs can result in withdrawal symptoms, known as discontinuation syndrome, which can include dizziness, headaches, and mood disturbances. Benzodiazepines, while effective for short-term use, carry a high risk of dependency, especially when used over extended periods. Long-term use of benzodiazepines can also lead to tolerance, where higher doses are needed to achieve the same therapeutic effect. This can create a cycle of dependence that is difficult to break and can result in withdrawal symptoms upon discontinuation, including rebound anxiety, insomnia, and, in severe cases, seizures [17].

Comparative Analysis of CBT and Pharmacotherapy

Short-term vs. long-term outcomes

When comparing CBT and pharmacotherapy, one of the key distinctions lies in the short-term versus long-term outcomes. Pharmacotherapy, particularly with SSRIs, tends to provide quicker relief of symptoms compared to CBT. This is particularly beneficial for individuals who are experiencing severe anxiety and need immediate symptom reduction to function in daily life [18]. However, the benefits of pharmacotherapy often diminish once the medication is discontinued, and many individuals experience a relapse of symptoms. In contrast, CBT may take longer to show its effects, but its benefits are more enduring. CBT teaches patients skills that they can continue to use long after the therapy has ended, reducing the risk of relapse [19]. Several studies have shown that the long-term efficacy of CBT is superior to that of pharmacotherapy, particularly when treatment is followed up with booster sessions or periodic check-ins with a therapist.

Patient adherence and preference

Patient adherence is another factor that differentiates CBT from pharmacotherapy. While some patients may find it easier to take medication as prescribed, others may struggle with the side effects, which can lead to non-compliance. In fact, one study found that up to 40% of patients discontinue SSRIs within the first three months due to side effects [19]. CBT, on the other hand, requires a more active role from the patient. It involves regular sessions with a therapist, homework assignments, and the willingness to confront and change long-standing thought patterns and behaviors. While this can be challenging, many patients find the process empowering and are more likely to adhere to the treatment because they feel a greater sense of control over their recovery. Moreover, studies have shown that patient preference often leans towards psychotherapy, especially for those who are hesitant to take medication long-term due to concerns about dependency or side effects.

Cost and accessibility

Both CBT and pharmacotherapy come with their own cost and accessibility considerations. Pharmacotherapy is generally more accessible, as medications can be prescribed by general practitioners and do not require specialized mental health professionals. However, the cost of medications, especially newer SSRIs and SNRIs, can be prohibitive for some individuals, particularly in countries without universal healthcare [20]. Additionally, individuals may need to remain on medication for extended periods, which can add to the long-term cost. CBT, while highly effective, can be expensive, particularly in areas where access to trained therapists is limited. The cost of 12 to 20 sessions can be significant, and in some cases, patients may need to wait several weeks or months to get an appointment with a qualified therapist [21]. Table 1 explains the comparison between CBT and Pharmacotherapy with all parameters.

Table 1. Comparative Analysis of CBT and Pharmacotherapy.

Parameter	Cognitive Behavioural Therapy (CBT)	Pharmacotherapy
Mechanism	Modifies thought patterns and behaviours to reduce anxiety symptoms	Alters brain chemistry using drugs like SSRIs, SNRIs, or benzodiazepines
Onset of Effect	Takes several weeks to months to show improvement	Quicker symptom relief, often within 2-4 weeks for SSRIs/SNRIs
Long-term Efficacy	Offers lasting benefits with lower relapse rates after treatment ends	Risk of symptom return after discontinuation; relapses common without maintenance
Side Effects	Minimal side effects (e.g., discomfort during exposure therapy)	Can cause nausea, insomnia, sexual dysfunction, or dependence (with benzodiazepines)
Patient Preference	Preferred by patients looking for skill-building and long-term strategies	Preferred for immediate relief and those averse to psychotherapy
Risk of Dependency	No dependency risks	Benzodiazepines carry significant dependency and withdrawal risks
Cost and Accessibility	Often higher cost due to need for trained therapists	More accessible via general practitioners; drug costs vary depending on region and insurance
Dropout Rates	Lower dropout rates compared to medication	Higher dropout rates due to side effects (up to 40% discontinue SSRIs within three months)
Effectiveness in Severe Cases	May be challenging for severely anxious patients to engage initially	More effective for immediate stabilization of acute symptoms
Combined Use	Works well with medications to enhance long-term outcomes	Recommended to combine SSRIs with CBT for comprehensive care

https://doi.org/10.61577/jmhbs.2024.1000010

Combined Treatment Approaches

The integration of CBT with pharmacotherapy has emerged as a promising approach for managing GAD. Both interventions are effective individually, yet evidence suggests that their combined use can offer superior clinical outcomes. Pharmacotherapy, especially with selective serotonin reuptake inhibitors (SSRIs), provides rapid symptom relief, which can be crucial for patients experiencing severe anxiety. This initial reduction in symptoms allows individuals to engage more effectively in CBT, focusing on cognitive restructuring and behavioral modification. CBT equips patients with long-term coping strategies, empowering them to manage anxiety without reliance on medication after treatment ends. In contrast, pharmacotherapy alone may carry risks of relapse once discontinued [22]. The combined approach mitigates this risk by addressing both the cognitive and neurochemical dimensions of anxiety disorders. Research highlights that patients receiving dual treatment show improved adherence and greater reductions in anxiety levels compared to those on monotherapy. This strategy is particularly beneficial for individuals with treatment-resistant GAD, who may not fully respond to either CBT or medication alone. Combining therapies creates a more comprehensive framework, where medication stabilizes acute symptoms and CBT fosters sustainable recovery. Studies also indicate that individuals with co-occurring disorders, such as depression, derive enhanced benefits from integrated treatment strategies (Table 2) [23].

Table 2. Steps explaining the combined treatment of GAD using CBT and Pharmacotherapy.

Step	Procedure	Details
Step 1: Initial Assessment	Conduct clinical evaluation and diagnosis of GAD.	Identify GAD symptoms and severity using diagnostic tools such as GAD-7 or DSM-5 criteria. Explore the patient history and any comorbid conditions.
Step 2: Educating the Patient	Provide information on GAD and treatment options.	Offer verbal and written details about CBT, pharmacotherapy, and their combination. Address patient concerns about side effects, withdrawal risks, and outcomes.
Step 3: Pharmacotherapy Initiation	Start with SSRIs like sertraline or escitalopram as the first-line medication.	Monitor for side effects during the initial 2-4 weeks. Adjust doses or switch to SNRIs if SSRIs are ineffective. Avoid benzodiazepines except for short-term crises.
Step 4: Initiating CBT Sessions	Begin CBT therapy with structured sessions focused on cognitive restructuring and behavioural modification.	Offer 12-15 weekly sessions of CBT, each lasting approximately 1 hour. Focus on addressing dysfunctional thought patterns and anxiety-inducing behaviours.
Step 5: Monitoring Treatment Progress	Regular follow-up sessions to assess symptom improvement and adherence.	Pharmacotherapy requires monitoring every 2-4 weeks initially, with periodic check-ins every 3 months thereafter. Evaluate CBT progress using standardized scales.
Step 6: Combined Approach Evaluation	Assess the effectiveness of the combined approach.	Determine if symptoms improve significantly with both CBT and medication. If not, consider adjusting therapy or switching medications.
Step 7: Preventing Relapse	Provide maintenance therapy to prevent relapse.	Continue pharmacotherapy for at least 6-12 months after symptom relief. Use CBT strategies as lifelong coping mechanisms to reduce anxiety recurrence.
Step 8: Tapering Medication (If Applicable)	Gradually reduce medication dosage after sustained improvement.	Monitor for withdrawal symptoms and ensure that CBT skills are well integrated to manage anxiety without pharmacotherapy.

Challenges and Limitations

Despite the proven efficacy of both CBT and pharmacotherapy, access to these treatments remains a significant challenge for many individuals suffering from GAD. A major barrier to accessing CBT is the shortage of trained mental health professionals, particularly in rural or underserved areas. Additionally, the cost of therapy sessions can be prohibitive for those without adequate health insurance, and long waiting lists for mental health services can delay treatment, posing problems for individuals in acute distress [24]. Pharmacotherapy, while generally more accessible through general practitioners, is not without its own obstacles. High medication costs, especially for newer antidepressants, can be a financial burden, and some patients may hesitate to start medication due to concerns about side effects or stigma surrounding mental health treatment. Another significant limitation of pharmacotherapy is the risk of side effects and dependency, particularly with benzodiazepines [25]. While SSRIs and SNRIs are considered safer for long-term use, they can cause gastrointestinal distress, insomnia, sexual dysfunction, and increased anxiety during initial treatment. Benzodiazepines, although effective for short-term relief, carry a high risk of dependency and tolerance, making them unsuitable for long-term use. Patients may require increasing doses over time, leading to a cycle of dependency, and withdrawal from these medications can cause rebound anxiety, further complicating treatment. These challenges highlight the importance of closely monitoring patients on long-term pharmacotherapy and considering alternative treatment options when appropriate [26].

https://doi.org/10.61577/jmhbs.2024.1000010

Conclusions

In conclusion, both CBT and pharmacotherapy are effective treatment options for managing GAD, with each offering unique advantages and limitations. CBT provides long-lasting therapeutic effects by teaching patients essential skills to manage and reduce anxiety, while pharmacotherapy offers quicker symptom relief, particularly for individuals with severe or acute anxiety. A comparative analysis of these treatments shows that CBT may be more suitable for long-term management and relapse prevention, while pharmacotherapy is helpful for immediate symptom alleviation. The combination of both treatments has been shown to offer enhanced benefits, especially for individuals who do not respond adequately to either treatment alone. However, challenges such as accessibility, cost, and potential side effects or dependency on medication can hinder the effectiveness of these treatments. Ultimately, treatment plans should be tailored to the individual's needs, preferences, and the severity of their symptoms. Further research is needed to continue improving treatment outcomes and to assess the efficacy of combined therapies across diverse populations.

Disclosure statement

The authors declare that there are no conflicts of interest that could affect the results or conclusions of this study.

References

1. Comer JS, Pincus DB, Hofmann SG. Generalized anxiety disorder and the proposed associated symptoms criterion change for DSM-5 in a treatment-seeking sample of anxious youth. Depress Anxiety. 2012;29(12):994-1003. https://doi.org/10.1002/da.21999
2. Renna ME, O'Toole MS, Fresco DM, Heimberg RG, Mennin DS. From psychological to physical health: Exploring temporal precedence throughout emotion regulation therapy. J Anxiety Disord. 2021;80:102403-102418. https://doi.org/10.1016/j.janxdis.2021
3. Renna ME, Hoyt MA, Ottaviani C, Mennin DS. An experimental examination of worry and relaxation on cardiovascular, endocrine, and inflammatory processes. Psychoneuroendocrinology. 2020;122: 104870-104885. https://doi.org/10.1016/j.psyneuen.2020.104870
4. Levy HC, O'Bryan EM, Tolin DF. A meta-analysis of relapse rates in cognitive-behavioral therapy for anxiety disorders. J Anxiety Disord. 2021;81:102407-102422. https://doi.org/10.1016/j.janxdis.2021.102407
5. LeBlanc NJ, Bartuska A, Blanchard L, Baker A, Bui E. Cognitive-behavioral treatment for generalized anxiety disorder: theoretical foundations and empirically supported strategies. Psychiatr Ann. 2021;51(5):210-215. https://doi.org/10.3928/00485713-20210412-02
6. Hirsch CR, Beale S, Grey N, Liness S. Approaching cognitive behavior therapy for generalized anxiety disorder from a cognitive process perspective. Front Psychiatry. 2019;10:796-804. https://doi.org/10.3389/fpsyt.2019.00796
7. Kaczkurkin AN, Foa EB. Cognitive-behavioral therapy for anxiety disorders: an update on the empirical evidence. Dialogues Clin Neurosci. 2015;17(3):337-346. https://doi.org/10.31887/DCNS.2015.17.3/akaczkurkin
8. Southward MW, Kushner ML, Terrill DR, Sauer-Zavala S. A Review of Transdiagnostic Mechanisms in Cognitive Behavior Therapy. Psychiatr Clin. 2024;47(2):343-354. https://doi.org/10.1016/j.psc.2024.02.003
9. Rapgay L, Bystritsky A, Dafter RE, Spearman M. New strategies for combining mindfulness with integrative cognitive behavioral therapy for the treatment of generalized anxiety disorder. J Ration Emot Cogn Behav Ther. 2011;29:92-119. https://doi.org/10.1007/s10942-009-0095-z
10. Cuijpers P, Sijbrandij M, Koole S, Huibers M, Berking M, Andersson G. Psychological treatment of generalized anxiety disorder: a meta-analysis. Clin Psychol Rev. 2014;34(2):130-140. https://doi.org/10.1016/j.cpr.2014.01.002
11. Guo F, Hanley T. Adapting cognitive behavioral therapy to meet the needs of Chinese clients: Opportunities and challenges. PsyCh J. 2015;4(2):55-65. https://doi.org/10.1002/pchj.75
12. Gomez AF, Barthel AL, Hofmann SG. Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review. Expert Opin Pharmacother. 2018;19(8):883-892. https://doi.org/10.1080/14656566.2018.1472767
13. Guina J, Merrill B. Benzodiazepines I: upping the care on downers: the evidence of risks, benefits and alternatives. J Clin Med. 2018;7(2):17-28. https://doi.org/10.3390/jcm7020017
14. James GM, Baldinger-Melich P, Philippe C, Kranz GS, Vanicek T, Hahn A. Effects of selective serotonin reuptake inhibitors on interregional relation of serotonin transporter availability in major depression. Front Hum Neurosci. 2017;11:48-62. https://doi.org/10.3389/fnhum.2017.00048
15. Bandelow B, Boerner R, Kasper S, Linden M, Wittchen HU, Möller HJ. The diagnosis and treatment of generalized anxiety disorder. Dtsch Arztebl Int. 2013;110(17):300-310. https://doi.org/10.3238/arztebl.2013.0300
16. Jing E, Straw-Wilson K. Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: a narrative literature review. Ment Health Clin. 2016;6(4):191-196. https://doi.org/10.9740/mhc.2016.07.191
17. Cabaj J, Bargieł J, Soroka E. Benzodiazepines and z-drugs-between treatment effectiveness and the risk of addiction. J Educ Health Sport. 2023;46(1):468-480. https://doi.org/10.12775/JEHS.2023.46.01.032
18. Cuijpers P, Hollon SD, van Straten A, et al. Does cognitive behaviour therapy have an enduring effect that is superior to keeping patients on continuation pharmacotherapy? A meta-analysis. BMJ Open. 2013;3(4):e002542-e002550. https://doi.org/10.1136/bmjopen-2012-002542
19. Leeuwerik T, Cavanagh K, Strauss C. Patient adherence to cognitive behavioural therapy for obsessive-compulsive disorder: A systematic review and meta-analysis. J Anxiety Disord. 2019;68: 102135-102150. https://doi.org/10.1016/j.janxdis.2019.102135
20. Koeser L, Donisi V, Goldberg DP, McCrone P. Modelling the cost-effectiveness of pharmacotherapy compared with cognitive–behavioural therapy and combination therapy for the treatment of moderate to severe depression in the UK. Psychol Med. 2015; 45(14):3019-3031. https://doi.org/10.1017/S0033291715000951
21. Wietersheim JV, Seitz B, Rottler E, Köppelmann N, Gündel H. Effort, Success and Failure while Seeking for Outpatient Psychotherapy-Results of a Prospective Study. Gesundheitswesen. 2019;83(1):40-46. https://doi.org/10.1055/a-1005-6958
22. Bayliss P, Holttum S. Experiences of antidepressant medication and cognitive–behavioural therapy for depression: A grounded theory study. Psychol Psychother Theory Res Pract. 2015;88(3):317-334. https://doi.org/10.1111/papt.12040
23. Hafiz R, Fairaq K, Alfawzan L, et al. Pharmaceutical Management of General Anxiety Disorder. J Pharm Res Int. 2021;33(57B):395-405. https://doi.org/10.9734/jpri/2021/v33i57B34072
24. Basile VT, Newton-John T, Wootton BM. Treatment histories, barriers, and preferences for individuals with symptoms of generalized anxiety disorder. J Clin Psychol. 2024;80(6):1286-1305. https://doi.org/10.1002/jclp.23665
25. Anderson C, Kirkpatrick S, Ridge D, Kokanovic R, Tanner C. Starting antidepressant use: a qualitative synthesis of UK and Australian data. BMJ Open. 2015;5(12):e008636-e008645. https://doi.org/10.1136/bmjopen-2015-008636
26. Kennedy KM, O'Riordan J. Prescribing benzodiazepines in general practice. Br J Gen Pract. 2019;69(680):152-153. https://doi.org/10.3399/bjgp19X701753

https://doi.org/10.61577/jmhbs.2024.1000010